Login to Your Account

FDA OKs Ocaliva for PBC; Biogen, Abbvie see new MS drug approved

By Michael Fitzhugh
Staff Writer

Tuesday, May 31, 2016

Patients living with primary biliary cholangitis, a rare chronic and gradually progressive liver disease, have gained a new second-line therapy with FDA approval for Intercept Pharmaceuticals Inc.'s Ocaliva.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription